Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Contradictory

<< Previous

Bullboard Posts

Next >>

Comment by Mannequinon Oct 30, 2023 10:10pm

102 Views

Post# 35708490

RE:RE:RE:RE:RE:Contradictory

And with the loose lips all around, you know people were selling like crazy hand over fist to get out before this occurred. And now jump back in when it's dirt cheap and they have the new crop of shareholders on board. What irks me is that we have lost 50% of the upside, and we should never have been here in the first place. The companies had was always in the sand. I certainly hope some heads roll.

Trogarzon wrote: Doing this at 25 cents for 50% dilution and then calling it a returning interest to sector is an insult to everyone that was a shareholder before the Government of Quebec. After telling everyone the price is stupid and unwarranted. Unreal.

<< Previous

Bullboard Posts

Next >>

Mullen Group: Navigates market challenges towards success